Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Dec;27(12):554-9.
doi: 10.1016/j.kjms.2011.06.029. Epub 2011 Nov 25.

Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma

Chia-I Lin  1 , Zu-Yau Lin, Ming-Yen Hsieh, Chung-Feng Huang, Su-Hwei Chen, Wan-Long Chuang
Affiliations
Clinical Trial

Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma

Chia-I Lin et al. Kaohsiung J Med Sci. 2011 Dec.

Abstract

The purpose of this study was to investigate the potential risk factors for the reactivation of the replication of hepatitis B virus (HBV) and hepatitis C virus (HCV) after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma. Forty-four hepatocellular carcinoma patients treated by TACE using epirubicin plus mitomycin C were studied. Serum HBV DNA (n=17) and HCV RNA (n=27) levels were measured 1 day before and 3 months after TACE. Plasma concentrations of chemotherapeutic agents were determined at 1 hour and 72 hours after TACE. A total of 29 patients (n=13 for chronic hepatitis Band n=16 for chronic hepatitis C) showed significant changes of the viral loads after TACE. Patients with increased viral loads after TACE were older (p=0.041), had higher incidence of pre-TACE white blood cell counts being less than normal limit (p=0.023), and had higher plasma mitomycin C concentrations (p=0.039) than those in patients with decreased viral loads. Analysis by multiple logistic regressions using age, decreased or normal pre-TACE white blood cell counts, mitomycin C concentrations >3.95 ng/mL adopted by receiver operating characteristic curve (p=0.037), and epirubicin concentrations have shown that decreased pre-TACE white blood cell counts was the only significant factor associated with increased viral loads after TACE (p=0.048). In conclusion, patients with decreased pre-TACE white blood cell counts have a potential risk for the reactivation of the replication of HBV or HCV after TACE.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma mitomycin C concentrations after transcatheter arterial chemoembolization. The higher plasma concentration of mitomycin C in two measurements was applied for analysis. •, increased viral loads after chemoembolization; ▲, decreased viral loads after chemoembolization. p  =  0.039 for total and p  >  0.05 for HBV and HCV (Mann‐Whitney test). HBV  =  hepatitis B virus; HCV  =  hepatitis C virus.
Figure 2
Figure 2
Plasma epirubicin concentrations after transcatheter arterial chemoembolization. The higher plasma concentration of epirubicin in two measurements was applied for analysis. •, Increased viral loads after chemoembolization; ▲, decreased viral loads after chemoembolization. p  >  0.05 for total, HBV, and HCV (Mann‐Whitney test). HBV  =  hepatitis B virus; HCV  =  hepatitis C virus.
See this image and copyright information in PMC

References

    1. Schutte K., Bornschein J., Malfertheiner P.. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis. 2009; 27: 80–92. - PubMed
    1. Cormier J.N., Thomas K.T., Chari R.S., Pinson C.W.. Management of hepatocellular carcinoma. J Gastrointest Surg. 2006; 10: 761–780. - PubMed
    1. Acunas B., Rozanes I.. Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization. Eur J Radiol. 1999; 32: 86–89. - PubMed
    1. Marelli L., Stigliano R., Triantos C., Senzolo M., Cholongitas E., Davies N., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007; 30: 6–25. - PubMed
    1. Hussain S.A., Ferry D.R., El‐Gazzaz G., Mirza D.F., James N.D., McMaster P., et al. Hepatocellular carcinoma. Ann Oncol. 2001; 12: 161–172. - PubMed

Publication types

MeSH terms